AOD-9604: The Fat-Loss Fragment That Almost Made It to Market (And Why the Phase 2 Result Mattered)

A pseudonymous reader walks through the actual Phase 2b obesity trial that almost no one in peptide-content world has read, and the quiet pivot from drug candidate to wellness ingredient.

by JoyBoy 11 min read Last reviewed May 2026 🟡 Human RCT (Phase 2, primary endpoint missed) Not FDA approved. Cosmetic / supplement marketing only.

Why I looked into this

AOD-9604 has one of the strangest trajectories of any compound on this site. It was a real drug candidate, developed by a real biotech, taken through real human trials, and it failed its pivotal efficacy test. Then it got a second life as a supplement ingredient and, eventually, as a cosmetic claim. The bodybuilding internet kept talking about it as if it were a working fat-loss molecule. The trial publication says otherwise.

I wanted to read the actual Phase 2b paper, look at the FDA paper trail around the GRAS notification, and figure out what the honest version of the AOD-9604 story is. The honest version is more interesting than the marketing version.

I have no personal experience with this compound. Everything in the opinion section at the bottom is opinion, full stop. The data section is data. They live in separate rooms.

What AOD-9604 actually is

AOD-9604 is a 16-amino-acid fragment of human growth hormone, corresponding to residues 177-191 of the HGH molecule, with a tyrosine added at the N-terminus. The thinking goes back to work in the 1990s on which segment of HGH might be responsible for the molecule’s effect on fat metabolism, separate from its growth-promoting and IGF-1-raising effects.

The pitch was elegant. If you could isolate the lipolytic tail of HGH from the rest of the molecule, you might get a compound that nudges fat metabolism without raising IGF-1, without affecting glucose handling the way HGH does, and without the regulatory baggage of a full growth hormone analog. Metabolic Pharmaceuticals, an Australian biotech, took the molecule into clinical development as an obesity drug candidate (initially oral, later in other formulations) in the early-to-mid 2000s. Mechanistic interest is not the same as clinical efficacy. The trial program is what tested whether the pitch worked in humans.

What the human research shows

Where the hype came from (and why it persists)

Three threads keep the AOD-9604 story alive in places it probably should have died.

Thread one: the mechanistic story is genuinely interesting. The idea that you can isolate one functional region of HGH and get its lipolytic effect without IGF-1 elevation is a clean and clever pitch. Clean pitches do not need to be true to keep getting repeated. The Phase 2b is the test of whether the pitch translated to a measurable human effect. The test came back negative on the primary endpoint.

Thread two: the GRAS designation gets misread as drug approval. In 2014, AOD-9604 received a Generally Recognized as Safe (GRAS) determination for use as a supplement ingredient under specific intended uses. GRAS is a safety designation under food and supplement law. It says, in effect, “this ingredient is safe enough to use in this category of product under these conditions.” It is not an efficacy claim. It is not drug approval. It is not the FDA telling anyone the compound works. Marketing copy regularly conflates these things.

Thread three: the cosmetic and topical preparations are a different conversation entirely. AOD-9604 has shown up in topical formulations marketed for skin and other cosmetic claims. That is a different route, a different concentration, a different intended use, and a different evidence base from the systemic obesity question that the Phase 2b actually tested. Topical claims do not validate systemic claims and vice versa.

FDA and legal status

The legal layer is the part most consumer-facing AOD-9604 marketing blurs. “FDA-recognized as safe” is not “FDA-approved drug.” “GRAS for supplement use” does not mean “approved for treating obesity.” Advisory-committee inclusion is not approval, GRAS designation is not approval, and an active marketing campaign is not approval. None of those constitute the FDA endorsing AOD-9604 as a working obesity drug.

How to evaluate a source: the safety framework

Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name sellers. I do not link to anyone. I am teaching you how to think about a source so you can have an informed conversation with a clinician.

The wrinkle for AOD-9604 specifically

This is the unusual case where the regulatory paper trail is the most important part of the source-safety conversation. A GRAS-status supplement ingredient and a compounded research-grade product marketed for systemic human use in obesity are categorically different products with different oversight. Anyone selling you the second one while citing the first is conflating two regulatory statuses on purpose.

Cost reality

The cost picture for AOD-9604 is whatever the gray-market and supplement supply chain wants it to be, because there is no FDA-approved drug version with a list price to anchor against. Cheap is not the same as effective. The Phase 2b trial used a clinical-grade product, and even that one missed its primary endpoint.

Questions worth asking any source

Where is this synthesized? Where is it independently tested? What is the chain of custody? What is the cited evidence for the claim being made, and does that evidence actually support the claim? A real source has answers and documents. A bad one has marketing copy and a price list.

My honest take

Questions to ask your doctor

If you are considering AOD-9604 for any reason, here are the questions I would want answered before walking out of the appointment, in order.

1. Have you read the Phase 2b publication on AOD-9604? The trial’s primary efficacy endpoint for weight loss versus placebo was not met. A clinician who can talk you through what that result means is a different conversation partner than one who cannot.
2. What is the actual claim you are making for this compound? Systemic weight loss is not what the trial supported. Topical or cosmetic claims sit in a different evidence base. Be specific about the claim.
3. Is this an FDA-approved drug, a GRAS-designated supplement ingredient, or a compounded research-grade product? These are three different regulatory categories with three different oversight levels. The answer should be specific and documented.
4. If we are using a compounded version, where is it synthesized, where is it independently tested, and what is the chain of custody? A real answer involves names of facilities and documents, not reassurance.
5. What is your stop condition? If we start, what would make us stop? “If it does not work” is not a clinical answer. A measurable outcome and a timeline is.
6. What other interventions for the underlying goal have we discussed? If the goal is weight management, the molecules with multiple successful Phase 3 trials behind them are a different category of conversation than a Phase 2-failed fragment.

What to do next

Sources

• Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. (Pre-clinical, included for completeness only.)
• Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. (Pre-clinical, included for completeness only.)
• Metabolic Pharmaceuticals Limited. Phase 2b clinical trial summary disclosures and subsequent ASX filings, 2007 and following. Industry funded (Metabolic Pharmaceuticals).
• Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15. Industry-affiliated authorship.
• US FDA. GRAS Notice (GRN) No. 525 for AOD-9604 (also referred to as the synthetic 16-amino-acid fragment of human growth hormone), 2014. Determination of Generally Recognized as Safe for specific intended uses as a supplement ingredient.
• Secondary review and discussion of the AOD-9604 obesity development program in subsequent literature on lipolytic peptides and HGH fragments.

Funding for the development program and the GRAS notification work was largely industry-affiliated. That is worth saying plainly. Industry funding does not invalidate the data, but it is part of how the data should be read, especially when the published narrative around a missed primary endpoint goes quieter than the narrative around earlier mechanistic claims.

Related monographs